Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

PHASE3RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

January 1, 2029

Study Completion Date

January 1, 2029

Conditions
ENSAT Stage I Adrenal Cortex CarcinomaENSAT Stage II Adrenal Cortex CarcinomaENSAT Stage III Adrenal Cortex Carcinoma
Interventions
DRUG

Cisplatin

Given IV

DRUG

Etoposide

Given IV

DRUG

Mitotane

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (23)

25000

RECRUITING

CHRU Jean Minjoz, Besançon

RECRUITING

Centre Georges François Leclerc, Dijon

29200

RECRUITING

CHU La Cavale Blanche, Brest

31059

RECRUITING

Hôpital Larrey, Toulouse

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

63110

ACTIVE_NOT_RECRUITING

Siteman Cancer Center at Washington University, St Louis

75014

NOT_YET_RECRUITING

Hôpital Cochin, Paris

RECRUITING

Hôpital COCHIN, Paris

77030

RECRUITING

M D Anderson Cancer Center, Houston

Unknown

RECRUITING

CHU Larrey, Angers

RECRUITING

Institut de Cancérologie de l'Ouest (ICO), Angers

RECRUITING

HCL Louis pradel, Lyon

RECRUITING

CHU René et Guillaume Laënnec, Nantes

RECRUITING

CHU René et Guillaume Laënnec, Nantes

RECRUITING

CHU Bordeaux - Hôpital, Pessac

RECRUITING

CHU Poitiers, Poitiers

RECRUITING

HUS Hautepierre, Strasbourg

RECRUITING

Hôpital Rangueil, Toulouse

RECRUITING

Gustave Roussy, Villejuif

RECRUITING

Sahlgrenska University Hospital, Gothenburg

RECRUITING

Karolinska University Hospital, Stockholm

RECRUITING

Akademiska Sjukhuset, Uppsala

44-102

RECRUITING

Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

collaborator

University Hospital Wurzburg

UNKNOWN

collaborator

University Hospital Munich

OTHER

collaborator

Skanes Universitetssjukhus

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT03583710 - Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence | Biotech Hunter | Biotech Hunter